RUZZI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 286
EU - Europa 205
AS - Asia 30
AF - Africa 16
SA - Sud America 2
Totale 539
Nazione #
US - Stati Uniti d'America 284
IT - Italia 70
DE - Germania 32
FR - Francia 28
IE - Irlanda 26
CN - Cina 16
BG - Bulgaria 13
EG - Egitto 12
VN - Vietnam 9
GB - Regno Unito 7
SE - Svezia 6
CH - Svizzera 5
FI - Finlandia 4
NL - Olanda 4
RU - Federazione Russa 4
UA - Ucraina 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 2
CA - Canada 2
CL - Cile 2
CZ - Repubblica Ceca 2
HK - Hong Kong 2
IN - India 1
Totale 539
Città #
Ashburn 27
Dublin 26
Bologna 23
Fairfield 23
Santa Cruz 22
Seattle 16
Columbus 15
Bremen 14
Sofia 13
Houston 12
Woodbridge 12
Buffalo 9
Chicago 7
Tappahannock 7
Cairo 6
Cambridge 6
Southend 6
Stockholm 6
Bern 5
Dong Ket 5
Wilmington 5
Ann Arbor 4
Boardman 4
Council Bluffs 4
Shanghai 4
Lappeenranta 3
Los Angeles 3
Naples 3
Paris 3
Rimini 3
Dallas 2
Dongguan 2
Fleming Island 2
Frankfurt am Main 2
Lake Forest 2
Las Vegas 2
Leverkusen 2
Milpitas 2
Muizenberg 2
New York 2
Rome 2
San Giovanni in Persiceto 2
Sunnyvale 2
Torino 2
Turin 2
Vicenza 2
Washington 2
Wuhan 2
Amsterdam 1
Atlanta 1
Bellevue 1
Büdelsdorf 1
Camerino 1
Cedar Knolls 1
Central District 1
Chengdu 1
Chieti 1
Clearwater 1
Crocetta 1
Crugers 1
Faenza 1
Gif-sur-Yvette 1
Guangzhou 1
Helsinki 1
Herndon 1
Jersey City 1
Milan 1
Modderfontein 1
Mountain View 1
Munger 1
Munich 1
Norwalk 1
Ottawa 1
Parma 1
Portici 1
Provo 1
Redmond 1
Reston 1
Saint Petersburg 1
San Benedetto del Tronto 1
San Diego 1
San Giorgio di Piano 1
San Jose 1
San Mateo 1
Scandiano 1
Silverton 1
Sulmona 1
Toronto 1
University Park 1
Utrecht 1
Zittau 1
Totale 375
Nome #
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations, file e1dcb333-0de2-7715-e053-1705fe0a6cc9 147
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft, file e1dcb337-0581-7715-e053-1705fe0a6cc9 77
IFN-γ and CD38 in Hyperprogressive Cancer Development, file e1dcb336-8df3-7715-e053-1705fe0a6cc9 73
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R, file e1dcb332-d495-7715-e053-1705fe0a6cc9 72
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC, file 60d6112b-a70b-4dc2-99bd-a748fdad85c5 23
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R, file e1dcb335-33b1-7715-e053-1705fe0a6cc9 20
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma, file e1dcb339-265a-7715-e053-1705fe0a6cc9 18
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression, file e1dcb338-7909-7715-e053-1705fe0a6cc9 17
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality, file 5630acdc-141c-4f7c-a4b3-db4f3187bb72 14
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine, file 205eec09-01c7-472c-80d7-400959bb2427 12
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma, file 9829c23c-a565-4fa3-87b2-566b1fa18734 12
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality, file 4d33c91d-e66d-4ece-ae99-b714c73030a9 11
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy, file a8377ff7-c7e1-4e95-aa8d-026ff578fbdf 11
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research, file 14f6015e-5ad1-48a8-b4f2-b6787fddbb2e 10
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality, file 4ead0436-71be-44f9-9021-f4b3c77b8576 9
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression, file cc726988-ca04-4893-af11-685d3898467b 8
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma, file ec521a88-6ad8-4a3f-b445-93d3ccff6f9a 8
IL-1 Family Members in Bone Sarcomas, file 72e2b5ee-938e-444a-be9c-bf944f821a38 5
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine, file d81481ab-2bbf-4db2-a07a-f00796d21ae3 2
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC, file 03b199ed-feb0-47f3-883c-ac51c7e13567 1
Totale 550
Categoria #
all - tutte 2.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.321


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202041 0 0 0 0 3 5 7 5 6 6 5 4
2020/202169 5 5 1 4 8 3 4 5 6 10 12 6
2021/2022117 8 12 6 6 12 6 8 6 9 8 27 9
2022/2023152 3 4 26 27 6 7 3 6 29 12 24 5
2023/2024171 12 4 12 20 14 35 22 16 9 12 15 0
Totale 550